The eruption of digital technologies and ICT has meant that, in recent decades, there has been an enormous presence of screens in people's lives and, above ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

These pictures can show up problems with the structure, or damage, in your brain. If a problem is seen on an MRI that could be linked to your seizures, it can help support a diagnosis of epilepsy. It ...

Tonic-clonic seizures are the type of epileptic seizure most people recognise. In the past they were called grand-mal seizures. Tonic-clonic seizures can have a generalised onset, meaning they affect ...

Seizures can have many causes, such as trauma, infection, metabolic disturbances, brain tumours and more. When no specific cause can be pinpointed, it’s known as idiopathic epilepsy. Idiopathic ...

in the treatment of primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy. According to IQVIA (IMS Health), Levetiracetam in Sodium Chloride Injection had US sales ...

WASHINGTON – The Supreme Court on Friday said it will decide whether a teenager with severe epilepsy can sue her Minnesota school after a lengthy fight over special accommodations. At the heart ...

in the treatment of primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy. According to IQVIA (IMS Health), Levetiracetam in Sodium Chloride Injection had US sales ...

and primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy." The said drug is a generic therapeutic equivalent of the Reference Listed Drug (RLD) from HQ Specialty ...

Datopotamab deruxtecan-dlnk significantly improves progression-free survival in HR-positive, HER2-negative breast cancer compared with chemotherapy. The TROPION-Breast01 trial showed a higher ...